Pay in 4 interest-free payments of $5.92 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
& Barker, R
Retatrutide (LY-3437943) is an investigational drug developed by Eli Lilly that acts as a triple hormone receptor agonist : GLP-1 (glucagon-like peptide-1) receptor agonist GIP (glucose-dependent insulinotropic polypeptide) receptor agonist Glucagon receptor agonist - read about why this is so important here This triagonist approach amplifies the metabolic impact seen with GLP-1 and GIP combinations like tirzepatide, while also leveraging glucagons thermogenic and energy-expending properties
Innovations in drug design and delivery Advancements in drug design and delivery can make GLP-1 agonist treatments, like semaglutide, much better
Appetite Changes: Loss of appetite is common, which contributes to weight loss
Sin embargo, algunas personas pueden experimentar efectos secundarios leves, como malestar estomacal, nuseas o diarrea
The gastric-emptying effect of long-acting GLP-1 receptor agonists may diminish over time (tachyphylaxis), but appetite suppression and reduced hunger typically persist throughout treatment
US$ 28.64
US$ 21.50
US$ 29.00
US$ 26.49
US$ 29.72
US$ 22.12
US$ 23.42
